Literature DB >> 32239559

Dual modulation of formyl peptide receptor 2 by aspirin-triggered lipoxin contributes to its anti-inflammatory activity.

Yunjun Ge1, Shuo Zhang2, Junlin Wang1, Fangbo Xia1, Jian-Bo Wan1, Jinjian Lu1, Richard D Ye1,3.   

Abstract

The eicosanoid lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 (ATL) are potent anti-inflammatory agents. How their anti-inflammatory effects are mediated by receptors such as the formyl peptide receptor 2 (FPR2/ALX) remains incompletely understood. In the present study, fluorescent biosensors of FPR2/ALX were prepared and ATL-induced conformational changes were recorded. A biphasic dose curve consisting of a descending phase and an ascending phase was observed, with the descending phase corresponding to diminished FPR2 response such as Ca2+ mobilization induced by the potent synthetic agonist WKYMVm. Preincubation of FPR2-expressing cells with 100 pM of ATL also lowered the threshold for WKYMVm to induce β-arrestin-2 membrane translocation, and inhibited WKYMVm-induced interleukin 8 secretion, suggesting signaling bias favoring anti-inflammatory activities. At 100 pM and above, ATL-induced receptor conformational changes resembling that of the WKYMVm along with a weak but measurable inhibition of forskolin-induced cAMP accumulation. However, no Ca2+ mobilization was induced by ATL until its concentration reached 1 µM. Taken together, these results suggest a dual regulatory mechanism by which ATL exerts anti-inflammatory effects through FPR2/ALX.
© 2020 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  G protein-coupled receptor; biased signaling; inflammation; inverse agonism

Year:  2020        PMID: 32239559     DOI: 10.1096/fj.201903206R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  13 in total

1.  Agonist concentration-dependent changes in FPR1 conformation lead to biased signaling for selective activation of phagocyte functions.

Authors:  Junlin Wang; Richard D Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-25       Impact factor: 12.779

2.  Neutrophil Immunomodulatory Activity of Farnesene, a Component of Artemisia dracunculus Essential Oils.

Authors:  Igor A Schepetkin; Gulmira Özek; Temel Özek; Liliya N Kirpotina; Andrei I Khlebnikov; Robyn A Klein; Mark T Quinn
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

3.  Deficit of resolution receptor magnifies inflammatory leukocyte directed cardiorenal and endothelial dysfunction with signs of cardiomyopathy of obesity.

Authors:  Bochra Tourki; Vasundhara Kain; Saame Raza Shaikh; Xavier Leroy; Charles N Serhan; Ganesh V Halade
Journal:  FASEB J       Date:  2020-06-16       Impact factor: 5.191

Review 4.  Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling.

Authors:  Maria Carmela Annunziata; Melania Parisi; Gabriella Esposito; Gabriella Fabbrocini; Rosario Ammendola; Fabio Cattaneo
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

5.  The N-Formyl Peptide Receptor 2 (FPR2) Agonist MR-39 Improves Ex Vivo and In Vivo Amyloid Beta (1-42)-Induced Neuroinflammation in Mouse Models of Alzheimer's Disease.

Authors:  Ewa Trojan; Kinga Tylek; Nicole Schröder; Iris Kahl; Lars-Ove Brandenburg; Margherita Mastromarino; Marcello Leopoldo; Agnieszka Basta-Kaim; Enza Lacivita
Journal:  Mol Neurobiol       Date:  2021-09-01       Impact factor: 5.590

6.  Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2.

Authors:  Youwen Zhuang; Lei Wang; Jia Guo; Dapeng Sun; Yue Wang; Weiyi Liu; H Eric Xu; Cheng Zhang
Journal:  Nat Commun       Date:  2022-02-25       Impact factor: 14.919

Review 7.  Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?

Authors:  Nils Helge Schebb; Hartmut Kühn; Astrid S Kahnt; Katharina M Rund; Valerie B O'Donnell; Nicolas Flamand; Marc Peters-Golden; Per-Johan Jakobsson; Karsten H Weylandt; Nadine Rohwer; Robert C Murphy; Gerd Geisslinger; Garret A FitzGerald; Julien Hanson; Claes Dahlgren; Mohamad Wessam Alnouri; Stefan Offermanns; Dieter Steinhilber
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

Review 8.  Targeting Neutrophils for Promoting the Resolution of Inflammation.

Authors:  János G Filep
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

Review 9.  Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology.

Authors:  Mauro Perretti; Catherine Godson
Journal:  Br J Pharmacol       Date:  2020-09-20       Impact factor: 8.739

Review 10.  A review of non-prostanoid, eicosanoid receptors: expression, characterization, regulation, and mechanism of action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2021-06-26       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.